Tag Archives: Takeda
Avandia Trial in Trouble
GSK’s Avandia just won’t stay out of the news. Now comes a report from The Wall Street Journal that the FDA is considering dealing the beleaguered diabetes drug another blow by stopping one of its safety trials.
The TIDE trial, which received approval in 2007, pits Avandia (rosiglitazone) against Takeda’s Actos (pioglitazone), a drug that [...]
Posted in Strategy Also tagged Actos, Avandia, FDA, Geodon, GSK, Pfizer, US Senate Finance Committee Leave a comment
Takeda Changes Dexlansoprazole Brand Name From Kapidex to Dexilant
Takeda’s US subsidiary launched its proton pump inhibitor dexlansoprazole last February under the name Kapidex. No one thought they’d have to find a new name a year later.
But shortly after the launch, the company began getting reports of dispensing errors. Some were due to prescription misreading, others to simple, honest mistakes. The two drugs causing [...]
Posted in Corporate Responsibility, FDA, Marketing, News, Safety, Strategy Also tagged Casodex, chronic pain, Dexilant, dexlansoprazole, dispensing error, FDA, Kadian, Kapidex, Prostate cancer, proton pump inhibitor 2 Comments
Gearing up: HBA Leadership Conference
Two thousand and eight seems to be a year of unprecedented female leadership. Forget for a second (if you can) the run-off for the Presidential election. If you just consider healthcare, the ladies are really stepping up—and making all the right moves. Consider a few examples: J&J names Sheri McCoy worldwide chairman of pharmaceuticals [...]
Posted in Events, Strategy Also tagged association, businesswoman, Charlotte Sibley, HBA, leader, meeting, Millenium, Women Leave a comment

Takeda Launches New Plan, Cuts US Jobs